In response to PD-1 blocking antibodies, the increased pool of progenitor exhausted CD8+ T cells caused by LSD1 inhibition provides a sustained source for the conversion to more differentiated T cells with stronger tumor-killing cytotoxicity, which enables a long-lasting response to anti-PD-1 treatment. This evidence concerns the gene KDM1A and neoplasm.